Biofortis Mérieux NutriSciences Clinical Investigation Center
Saint-Herblain, 44800, France
NCT Number: NCT02817620
The purpose of this pilot study is to assess the beneficial effect of a spirulina water extract (product named Spirulysat®) compared to a placebo in the blood level ratio of oxidized LDL / total LDL cholesterol in subjects with metabolic syndrome after 12 weeks of consumption
Looking for future studies?
Notify Me18 year–65 year
All sexes
Interventional
Not applicable
Saint-Herblain, 44800, France
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
To be eligible to the study, male and female volunteers will have to fulfil the following criteria (assessment based on the medical examination performed at V0 with a checking at V1):
After V0 biological analysis the subjects will be eligible to the study on the following criterion :
A re-screening can occur from 2 months after the exit of the study for failure to comply with one or more of the inclusion criteria listed above.
Exclusion criteria
Volunteers with the following criteria will be considered as non eligible to the study (assessment based on the medical examination performed at V0 with a checking at V1):
After V0 biological analysis the subjects will be considered as non eligible to the study on the following criteria :
A re-screening can occur from 2 months after the exit of the study for failure to comply with one or more of the exclusion criteria listed above.
Time frame: 12 weeks
Defined as the difference V3 (12 weeks) - V1 (baseline) in mU/g
Time frame: 6 weeks
Defined as the difference V2 (6 weeks) - V1 (baseline) in mU/g
Time frame: 6 weeks
Defined as the difference V2 (6 weeks) - V1 (baseline) in mU/L
Time frame: 12 weeks
Defined as the difference V3 (12 weeks) - V1 (baseline) in mU/L
Time frame: 6 weeks
Defined as the difference V2 (6 weeks) - V1 (baseline) in g/L
Time frame: 12 weeks
Defined as the difference V3 (12 weeks) - V1 (baseline) in g/L
Time frame: 6 weeks
Defined as the difference V2 (6 weeks) - V1 (baseline) in mg/L
Time frame: 12 weeks
Defined as the difference V3 (12 weeks) - V1 (baseline) in mg/L
Time frame: 6 weeks
Defined as the difference V2 (6 weeks) - V1 (baseline) in mmol/L
Time frame: 12 weeks
Defined as the difference V3 (12 weeks) - V1 (baseline) in mmol/L
Time frame: 6 weeks
Defined as the difference V2 (6 weeks) - V1 (baseline) in µkat/L
Time frame: 12 weeks
Defined as the difference V3 (12 weeks) - V1 (baseline) in µkat/L
Time frame: 6 weeks
Defined as the difference V2 (6 weeks) - V1 (baseline) in µkat/L
Time frame: 12 weeks
Defined as the difference V3 (12 weeks) - V1 (baseline) in µkat/L
Time frame: 6 weeks
Defined as the difference V2 (6 weeks) - V1 (baseline) in mmol/L
Time frame: 12 weeks
Defined as the difference V3 (12 weeks) - V1 (baseline) in mmol/L
Time frame: 6 weeks
Defined as the difference V2 (6 weeks) - V1 (baseline) in ng/mL
Time frame: 12 weeks
Defined as the difference V3 (12 weeks) - V1 (baseline) in ng/mL
Time frame: Baseline
Time frame: 6 weeks
Time frame: 12 weeks
Time frame: Baseline
Time frame: 6 weeks
Time frame: 12 weeks
Time frame: Baseline
Time frame: 6 weeks
Time frame: 12 weeks
Time frame: Baseline
Time frame: 6 weeks
Time frame: 12 weeks
Time frame: Baseline
Time frame: 6 weeks
Time frame: 12 weeks
Time frame: Baseline
Time frame: 12 weeks
Time frame: Baseline
Time frame: 12 weeks
Time frame: 6 weeks
Defined as the difference V2 (6 weeks) - V1 (baseline) in kg
Time frame: 12 weeks
Defined as the difference V3 (12 weeks) - V1 (baseline) in kg
Time frame: 6 weeks
Defined as the difference V2 (6 weeks) - V1 (baseline) in kcal/day
Time frame: 12 weeks
Defined as the difference V3 (12 weeks) - V1 (baseline) in kcal/day
Time frame: 6 weeks
Defined as the difference V2 (6 weeks) - V1 (baseline) in %
Time frame: 12 weeks
Defined as the difference V3 (12 weeks) - V1 (baseline) in %
Time frame: 6 weeks
Defined as the difference V2 (6 weeks) - V1 (baseline) in %
Time frame: 12 weeks
Defined as the difference V3 (12 weeks) - V1 (baseline) in %
Time frame: 6 weeks
Defined as the difference V2 (6 weeks) - V1 (baseline) in %
Time frame: 12 weeks
Defined as the difference V3 (12 weeks) - V1 (baseline) in %
Time frame: 6 weeks
Defined as the difference V2 (6 weeks) - V1 (baseline) in g/day (absolute quantities)
Time frame: 12 weeks
Defined as the difference V3 (12 weeks) - V1 (baseline) in g/day (absolute quantities)
Time frame: 6 weeks
Defined as the difference V2 (6 weeks) - V1 (baseline) in g/day (absolute quantities)
Time frame: 12 weeks
Defined as the difference V3 (12 weeks) - V1 (baseline) in g/day (absolute quantities)
Time frame: 6 weeks
Defined as the difference V2 (6 weeks) - V1 (baseline) in g/day (absolute quantities)
Time frame: 12 weeks
Defined as the difference V3 (12 weeks) - V1 (baseline) in g/day (absolute quantities)
Time frame: 6 weeks
Defined as the difference V2 (6 weeks) - V1 (baseline) in g/day (absolute quantities)
Time frame: 12 weeks
Defined as the difference V3 (12 weeks) - V1 (baseline) in g/day (absolute quantities)
Time frame: Pre-inclusion (V0), Baseline (V1), 6 weeks (V2) and 12 weeks (V3)
Time frame: Pre-inclusion (V0), Baseline (V1), 6 weeks (V2) and 12 weeks (V3)
Time frame: Pre-inclusion (V0), Baseline (V1), 6 weeks (V2) and 12 weeks (V3)
Algosource
Industry
Pilot Study to Assess Antioxidant Efficacy of a Spirulina Water Extract on Oxidized LDL Status and Lipids Metabolism on Subjects With Metabolic Syndrome
Acronym: SPIROX
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05956886
Dyssomnias, Glucose Metabolism Disorders
Newark, Delaware, United States
View Trial DetailsNCT07739602
Glucose Metabolism Disorders, Hyperinsulinism
Wroclaw, Poland
View Trial DetailsNCT04057339
Behavior, Fasting
La Jolla, California, United States
View Trial DetailsNCT07702669
Glucose Metabolism Disorders, Hyperinsulinism
Harbin, Heilongjiang, China
View Trial Details